Spire Healthcare Group (LON:SPI) Stock Price Down 18.1% After Analyst Downgrade

Shares of Spire Healthcare Group plc (LON:SPI) traded down 18.1% during trading on Thursday after Deutsche Bank Aktiengesellschaft lowered their price target on the stock from GBX 320 to GBX 300. Deutsche Bank Aktiengesellschaft currently has a buy rating on the stock. Spire Healthcare Group traded as low as GBX 169 ($2.18) and last traded at GBX 183.95 ($2.38). 8,024,729 shares were traded during mid-day trading, an increase of 1,005% from the average session volume of 726,218 shares. The stock had previously closed at GBX 224.50 ($2.90).

Spire Healthcare Group Stock Down 6.0 %

The stock has a fifty day moving average price of GBX 227.28 and a two-hundred day moving average price of GBX 229.74. The company has a debt-to-equity ratio of 62.25, a current ratio of 0.70 and a quick ratio of 0.74. The company has a market cap of £711.58 million, a P/E ratio of 25.22, a price-to-earnings-growth ratio of 1.06 and a beta of 0.96.

Spire Healthcare Group (LON:SPI) last released its quarterly earnings results on Thursday, March 6th. The company reported GBX 8.80 ($0.11) earnings per share for the quarter. Spire Healthcare Group had a net margin of 1.96% and a return on equity of 3.82%. On average, research analysts expect that Spire Healthcare Group plc will post 15.6634747 EPS for the current year.

Spire Healthcare Group Company Profile

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.